Amphastar Pharmaceuticals, Inc. (AMPH) 8-K Current Report: March 6, 2026
Filed: March 6, 2026
Health Care
Pharmaceutical PreparationsAmphastar Pharmaceuticals, Inc. (AMPH) 8-K current report filed with SEC EDGAR on March 6, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 5.02: Departure/Election of Directors or Officers
Amphastar Pharmaceuticals, Inc. 8-K Mar 6, 2026 Event Analysis
Item 5.02 · Departure/Election of Directors or Officers
- • Liawatidewi (EVP Corporate Admin, Secretary, Board member): $525,800 base salary + 55% target bonus
- • Zhou (Sr. EVP Production): $590,000 base salary + 53% target bonus
- • Severance on qualifying termination: 2x (highest base salary + avg 2-year bonus) plus 12 months health coverage and 100% equity acceleration
- • Change-in-control double-trigger adds another 2x cash lump sum and additional 12 months health premiums on top of standard severance
- • Full equity acceleration triggered by change-in-control alone, regardless of termination — notable shareholder dilution risk in M&A scenarios
Other Amphastar Pharmaceuticals, Inc. 8-K Filings
Get deeper insights on Amphastar Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.